Guidance on Infection Control in Schools and Other Childcare Settings March 2017
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Roseola Fact Sheet
Sixth Disease/ Exanthem Subitum DISTRICT OF COLUMBIA DEPARTMENT OF HEALTH Division of Epidemiology, Disease Surveillance and Investigation 899 N. Capitol Street, NE, Suite 580 Washington, D.C. 20002 202-442-9371 Fax 202-442-8060 * www.dchealth.dc.gov What is Roseola? medications. Frequent hand washing may Roseola is an acute, febrile rash illness caused by a limit transmission (spread). Women who are virus. pregnant and have been exposed to this illness should discuss the exposure with Who gets Fifth Disease? their doctor. Roseola occurs in children usually under four years of age. It is most common in children under the age Should a child with Roseola be excluded of two. from Child-care? Yes, a child with fever and rash should be What are the symptoms of Roseola? excluded from child-care until seen by a The symptoms of roseola include a high fever that health-care provider. The child may return lasts for three to five days. A runny nose, irritability, to child-care once the fever has gone, even if eyelid swelling, and tiredness may also be present. the rash is present. When the fever disappears, a rash appears, mainly on the face and body. How can Roseola be prevented? There is no vaccine or medicine that How is Roseola spread? prevents roseola. Frequent and thorough Roseola is spread from person to person but the hand washing is recommended as a practical exact way is not known. It appears that saliva may be and effective method of preventing most an important way for the spread of the virus. -
Communicable Disease Chart
COMMON INFECTIOUS ILLNESSES From birth to age 18 Disease, illness or organism Incubation period How is it spread? When is a child most contagious? When can a child return to the Report to county How to prevent spreading infection (management of conditions)*** (How long after childcare center or school? health department* contact does illness develop?) To prevent the spread of organisms associated with common infections, practice frequent hand hygiene, cover mouth and nose when coughing and sneezing, and stay up to date with immunizations. Bronchiolitis, bronchitis, Variable Contact with droplets from nose, eyes or Variable, often from the day before No restriction unless child has fever, NO common cold, croup, mouth of infected person; some viruses can symptoms begin to 5 days after onset or is too uncomfortable, fatigued ear infection, pneumonia, live on surfaces (toys, tissues, doorknobs) or ill to participate in activities sinus infection and most for several hours (center unable to accommodate sore throats (respiratory diseases child’s increased need for comfort caused by many different viruses and rest) and occasionally bacteria) Cold sore 2 days to 2 weeks Direct contact with infected lesions or oral While lesions are present When active lesions are no longer NO Avoid kissing and sharing drinks or utensils. (Herpes simplex virus) secretions (drooling, kissing, thumb sucking) present in children who do not have control of oral secretions (drooling); no exclusions for other children Conjunctivitis Variable, usually 24 to Highly contagious; -
THROMBOCYTOPENIA: OUTCOMES of VARICELLA in ADULTS 1Amber Arshad, 2Dr
IAJPS 2018, 05 (12), 14370-14373 Amber Arshad et al ISSN 2349-7750 CODEN [USA]: IAJPBB ISSN: 2349-7750 INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES http://doi.org/10.5281/zenodo.1976759 Available online at: http://www.iajps.com Research Article THROMBOCYTOPENIA: OUTCOMES OF VARICELLA IN ADULTS 1Amber Arshad, 2Dr. Shafia Masood, 3Dr. Zarwa Shahid 1FMH Collage of Medicine and Dentistry, Lahore-Pakistan 2Holy Family Hospital Rawalpindi 3House Officer, Jinnah Hospital Lahore Abstract: Objectives: The purpose of this research work is to elaborate the seriousness and rate of the low quantity of the platelets in the blood having relation with adult patients suffering of chickenpox. Methodology: This was a descriptive research work carried out in Mayo hospital Lahore and the duration of this research work was from January 2015 to March 2018 in the department of infectious diseases. In this study, record of the demographics, medical data, and blood & biochemical alterations created for each and every patient. The entry of this data carried out on a special organized form. Patients with previous background of CLD (chronic liver disease), drug addicts, HIV patients, blood abnormalities, or consumers of the wine were not the part of this research work. The count of the full blood with count of the platelet conducted with the help of an automated BCM (Beckman Coulter machine). The verification of the haematological results, the patients having low quantity of the platelet underwent PSE (peripheral smear examination). Results: One hundred and ten patients were the participant of this research work. The average age of the patients was 32.9 ± 9.7 years. -
Cutaneous Manifestations of HIV Infection Carrie L
Chapter Title Cutaneous Manifestations of HIV Infection Carrie L. Kovarik, MD Addy Kekitiinwa, MB, ChB Heidi Schwarzwald, MD, MPH Objectives Table 1. Cutaneous manifestations of HIV 1. Review the most common cutaneous Cause Manifestations manifestations of human immunodeficiency Neoplasia Kaposi sarcoma virus (HIV) infection. Lymphoma 2. Describe the methods of diagnosis and treatment Squamous cell carcinoma for each cutaneous disease. Infectious Herpes zoster Herpes simplex virus infections Superficial fungal infections Key Points Angular cheilitis 1. Cutaneous lesions are often the first Chancroid manifestation of HIV noted by patients and Cryptococcus Histoplasmosis health professionals. Human papillomavirus (verruca vulgaris, 2. Cutaneous lesions occur frequently in both adults verruca plana, condyloma) and children infected with HIV. Impetigo 3. Diagnosis of several mucocutaneous diseases Lymphogranuloma venereum in the setting of HIV will allow appropriate Molluscum contagiosum treatment and prevention of complications. Syphilis Furunculosis 4. Prompt diagnosis and treatment of cutaneous Folliculitis manifestations can prevent complications and Pyomyositis improve quality of life for HIV-infected persons. Other Pruritic papular eruption Seborrheic dermatitis Overview Drug eruption Vasculitis Many people with human immunodeficiency virus Psoriasis (HIV) infection develop cutaneous lesions. The risk of Hyperpigmentation developing cutaneous manifestations increases with Photodermatitis disease progression. As immunosuppression increases, Atopic Dermatitis patients may develop multiple skin diseases at once, Hair changes atypical-appearing skin lesions, or diseases that are refractory to standard treatment. Skin conditions that have been associated with HIV infection are listed in Clinical staging is useful in the initial assessment of a Table 1. patient, at the time the patient enters into long-term HIV care, and for monitoring a patient’s disease progression. -
A Review of Cutaneous Manifestations in Newborn Infants
Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2017, 9[3]:1-8 [http://scholarsresearchlibrary.com/archive.html] ISSN 0975-5071 USA CODEN: DPLEB4 A Review of Cutaneous Manifestations in Newborn Infants Mohammad Ali Shakeri Hosseinabad* Ahvaz Jundishapur University of Medical Sciences, Resident of Dermatology, Ahvaz, Iran. *Corresponding author: Mohammad Ali Shakeri Hosseinabad, Ahvaz Jundishapur University of Medical Sciences, Resident of Dermatology, Ahvaz, Iran, Email: [email protected] _______________________________________________________ ABSTRACT Introduction: manifestations are very common in infants, and it can be a serious concern for parents, although most of them are benign and transient but some of them need further evaluation, accordingly knowledge about manifestations associated with infants can be an effective aid in the early diagnosis and treatment. The range of skin disorders is very wide. Timely examination of the skin in infants and control them is a good indicator to maintain the health of babies. Material and method: The required information through searching key words like: cutaneous manifestations, rashes, cutaneous infections, neonatal acne, early diagnosis, by Google Scholar, PubMed, Scopus, Magiran, Sid and Irandoc [from 1990 to 2016] was done Which some relevant articles were found and examined. Among 82 articles only 19 papers were quite relevant to cutaneous rashes. Findings: The first review of articles associated with this disease and infection and cutaneous rashes among infants and early diagnosis make a great help in timely treatment. Conclusion: one of the common cutaneous diseases is rashes, which treatment of bacterial or viral rashes is depends on its cause. Since that time of the disease is limited, in many patients and people with mild symptoms, do not need treatment. -
Randomised Trial to Compare the Immunogenicity and Safety of a CRM Or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenag
Title Page Randomised trial to compare the immunogenicity and safety of a CRM or TT 1 2 conjugated quadrivalent meningococcal vaccine in teenagers who received a 3 4 5 CRM or TT conjugated serogroup C vaccine at preschool age 6 7 8 9 1,2 1,3 1 10 David A. Ishola , FFPH; Nick Andrews , PhD; Pauline Waight , BSc; Chee-Fu 11 12 Yung1,6, FFPH; Jo Southern1, PhD; Xilian Bai4, PhD; Helen Findlow4, PhD; Mary 13 14 5 5 5 4 15 Matheson , PhD; Anna England , MSc; Bassam Hallis , PhD; Jamie Findlow , PhD; 16 4 1 17 Ray Borrow , PhD; Elizabeth Miller , FRCPath. 18 19 1. Immunisation Department, Public Health England (PHE), London, UK 20 21 22 2. Department of Infection and Population Health, University College London, 23 24 London, UK 25 26 27 3. Statistics, Modelling, and Economics Department, PHE London, UK 28 29 4. Vaccine Evaluation Unit, PHE, Manchester Medical Microbiology Partnership, 30 31 32 Manchester Royal Infirmary, Manchester, UK 33 34 5. Microbiology Services, PHE, Porton Down, Salisbury, UK 35 36 6. Department of Clinical Epidemiology, Communicable Disease Centre, Tan Tock 37 38 39 Seng Hospital, Singapore. 40 41 Correspondence: David Ishola, University College London, Department of Infection 42 43 44 and Population Health, 222 Euston Road, London NW1 2DA, UK. Tel: +44 45 46 (0)7946412701. Fax: +44 (0)20 83277404. E-mail: [email protected] 47 48 49 Address for reprints: Not applicable (reprints not available). 50 51 Key words: Meningococcal, vaccine, teenagers, antibody, randomised trial 52 53 54 Abbreviated title: Teenage MenACWY booster vaccination: Randomised trial 55 56 Running head title: Teenage MenACWY booster vaccination 57 58 59 60 61 62 1 63 64 65 CONFLICTS OF INTEREST AND SOURCE OF FUNDING: 1 2 Funding and support: This report is independent research commissioned and 3 4 5 funded by the UK Department of Health Policy Research Programme (National 6 7 Vaccine Evaluation Consortium, 039/0031). -
The NHS's Role in the Public's Health
The NHS’s role in the public’s health A report from the NHS Future Forum Workstream members Vicky Bailey ‐ Chair, NHS’s role in the public’s health group Chief Operating Officer, Principia Rushcliffe Clinical Commissioning Group Ash Soni ‐ Chair, NHS’s role in the public’s health group Community Pharmacist; Clinical Network Lead, NHS Lambeth Dr Charles Alessi Senior GP Partner, The Churchill Practice Dr Frank Atherton President, Association of Directors of Public Health; Director of Public Health, North Lancashire Cluster Ratna Dutt Chief Executive, Race Equality Foundation Paul Farmer Chief Executive, Mind Moira Gibb Chief Executive, London Borough of Camden; Chair, Social Work Task Force Chris Long Chief Executive, Humber Cluster Claire Marshall Head of Professions, Heatherwood and Wexham Park Hospitals NHS Foundation Trust Dr Tim Riley Chief Executive, Wellstate Group Ltd Tom Riordan Chief Executive, Leeds City Council Dr Robina Shah Chair, Stockport NHS Foundation Trust Professor Jimmy Steele Head of School and Professor of Oral Health Services Research, School of Dental Sciences, Newcastle University Gill Walton Director of Midwifery, Portsmouth Hospitals NHS Trust Contents Contents.........................................................................................................................2 Foreword........................................................................................................................3 Terms used in this report...............................................................................5 -
COVID-19 Vaccination Programme: Information for Healthcare Practitioners
COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1. -
Clinical Impact of Primary Infection with Roseoloviruses
Available online at www.sciencedirect.com ScienceDirect Clinical impact of primary infection with roseoloviruses 1 2 1 Brenda L Tesini , Leon G Epstein and Mary T Caserta The roseoloviruses, human herpesvirus-6A -6B and -7 (HHV- infection in different cell types, have the ability to reac- 6A, HHV-6B and HHV-7) cause acute infection, establish tivate, and may be intermittently shed in bodily fluids [3]. latency, and in the case of HHV-6A and HHV-6B, whole virus Unlike other human herpesviruses, HHV-6A and HHV- can integrate into the host chromosome. Primary infection with 6B are also found integrated into the host genome HHV-6B occurs in nearly all children and was first linked to the (ciHHV-6). Integration has been documented in 0.2– clinical syndrome roseola infantum. However, roseolovirus 1% of the general population and along with latency infection results in a spectrum of clinical disease, ranging from has confounded the ability to correlate the presence of asymptomatic infection to acute febrile illnesses with severe viral nucleic acid with active disease [4]. neurologic complications and accounts for a significant portion of healthcare utilization by young children. Recent advances The syndrome known as roseola infantum was reported as have underscored the association of HHV-6B and HHV-7 early as 1809 by Robert Willan in his textbook ‘On primary infection with febrile status epilepticus as well as the cutaneous diseases’ [5]. This clinical entity is also com- role of reactivation of latent infection in encephalitis following monly referred to as exanthem subitum and early pub- cord blood stem cell transplantation. -
Measles Diagnostic Tool
Measles Prodrome and Clinical evolution E Fever (mild to moderate) E Cough E Coryza E Conjunctivitis E Fever spikes as high as 105ºF Koplik’s spots Koplik’s Spots E E Viral enanthem of measles Rash E Erythematous, maculopapular rash which begins on typically starting 1-2 days before the face (often at hairline and behind ears) then spreads to neck/ the rash. Appearance is similar to “grains of salt on a wet background” upper trunk and then to lower trunk and extremities. Evolution and may become less visible as the of rash 1-3 days. Palms and soles rarely involved. maculopapular rash develops. Rash INCUBATION PERIOD Fever, STARTS on face (hairline & cough/coryza/conjunctivitis behind ears), spreads to trunk, Average 8-12 days from exposure to onset (sensitivity to light) and then to thighs/ feet of prodrome symptoms 0 (average interval between exposure to onset rash 14 day [range 7-21 days]) -4 -3 -2 -1 1234 NOT INFECTIOUS higher fever (103°-104°) during this period rash fades in same sequence it appears INFECTIOUS 4 days before rash and 4 days after rash Not Measles Rubella Varicella cervical lymphadenopathy. Highly variable but (Aka German Measles) (Aka Chickenpox) Rash E often maculopapular with Clinical manifestations E Clinical manifestations E Generally mild illness with low- Mild prodrome of fever and malaise multiforme-like lesions and grade fever, malaise, and lymph- may occur one to two days before may resemble scarlet fever. adenopathy (commonly post- rash. Possible low-grade fever. Rash often associated with painful edema hands and feet. auricular and sub-occipital). -
A Synopsis of the Joint Environment and Human Health Programme in the UK Michael N Moore*1 and Pamela D Kempton2
Environmental Health BioMed Central Introduction Open Access A synopsis of the Joint Environment and Human Health Programme in the UK Michael N Moore*1 and Pamela D Kempton2 Address: 1Plymouth Marine Laboratory, Prospect Place, the Hoe, Plymouth, PL1 3DH, UK and 2Natural Environment Research Council, Polaris House, North Star Avenue, Swindon, SN2 1EU, UK Email: Michael N Moore* - [email protected]; Pamela D Kempton - [email protected] * Corresponding author from Joint Environment and Human Health Programme: Annual Science Day Conference and Workshop Birmingham, UK. 24-25 February 2009 Published: 21 December 2009 Environmental Health 2009, 8(Suppl 1):S1 doi:10.1186/1476-069X-8-S1-S1 <supplement>Sciences Research <title> Council <p>Proceedings (BBSRC), Engineering of the Joint and Environment Physical Sciences and Human Research Health Council Programme: (EPSRC) Annual and Health Science Protection Day Conference Agency (HPAand Work).</note>shop</p> </sponsor> </title> <note>Proceedings</note> <editor>Michael N Moore <url>http://www.biomedcentral.com/content/pdf/1476-069X-8-s1-info.pdf</url>and Pamela D Kempton</editor> <sponsor> <note>Publication of this supplement </sup wasplement> made possible with support from the Natural Environment Research Council (NERC), Environment Agency (EA), Department of the Environment & Rural Affairs (Defra), Ministry of Defence (MOD), Medical Research Council (MRC), The Wellcome Trust, Economic & Social Research Council (ESRC), Biotechnology and Biological This article is available from: http://www.ehjournal.net/content/8/S1/S1 © 2009 Moore and Kempton; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. -
The Impact on Health of Emissions to Air from Municipal Waste Incinerators
The Impact on Health of Emissions to Air from Municipal Waste Incinerators Advice from the Health Protection Agency RCE-13 The Impact on Health of Emissions to Air from Municipal Waste Incinerators Advice from the Health Protection Agency Documents of the Health Protection Agency Radiation, Chemical and Environmental Hazards February 2010 © Health Protection Agency 2010 Contents The Impact on Health of Emissions to Air from Municipal Waste Incinerators Advice from the Health Protection Agency 1 Summary 1 Introduction 3 Particles 4 Carcinogens 8 Dioxins 9 Epidemiological studies: municipal waste incinerators and cancer 11 Conclusions 11 References 12 Glossary 14 The Impact on Health of Emissions to Air from Municipal Waste Incinerators Advice from the Health Protection Agency Prepared by R L Maynard, H Walton, F Pollitt and R Fielder Summary The Health Protection Agency has reviewed research undertaken to examine the suggested links between emissions from municipal waste incinerators and effects on health. While it is not possible to rule out adverse health effects from modern, well regulated municipal waste incinerators with complete certainty, any potential damage to the health of those living close-by is likely to be very small, if detectable. This view is based on detailed assessments of the effects of air pollutants on health and on the fact that modern and well managed municipal waste incinerators make only a very small contribution to local concentrations of air pollutants. The Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment has reviewed recent data and has concluded that there is no need to change its previous advice, namely that any potential risk of cancer due to residency near to municipal waste incinerators is exceedingly low and probably not measurable by the most modern techniques.